Assembly Biosciences (ASMB) Projected to Announce Earnings on Monday

Assembly Biosciences (NASDAQ:ASMB) is anticipated to announce its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect Assembly Biosciences to post earnings of ($0.6550) per share and revenue of $9.07 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Assembly Biosciences (NASDAQ:ASMB) last issued its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.52. The company had revenue of $13.37 million for the quarter, compared to the consensus estimate of $8.60 million. Assembly Biosciences had a negative return on equity of 0.02% and a negative net margin of 0.06%. On average, analysts expect Assembly Biosciences to post $2.28 EPS for the current fiscal year and $0.05 EPS for the next fiscal year.

Assembly Biosciences Price Performance

Shares of Assembly Biosciences stock opened at $20.13 on Monday. The business has a 50-day moving average price of $26.14 and a 200-day moving average price of $27.24. Assembly Biosciences has a twelve month low of $19.30 and a twelve month high of $39.71. The firm has a market cap of $409.85 million, a price-to-earnings ratio of 19.74 and a beta of 1.26.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Mizuho set a $53.00 target price on shares of Assembly Biosciences in a research report on Tuesday, September 1st. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Assembly Biosciences in a research report on Tuesday, August 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Thursday, October 15th. Zacks Research raised Assembly Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 20th. Finally, UBS Group started coverage on Assembly Biosciences in a report on Tuesday, September 1st. They issued a “buy” rating and a $52.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Assembly Biosciences has a consensus rating of “Moderate Buy” and an average target price of $47.50.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc is a clinical-stage biotechnology company focused on developing oral therapeutics for serious viral infections. The company’s research programs target chronic hepatitis B virus (HBV) infection and herpesvirus infections, including herpes simplex virus (HSV), with the goal of addressing diseases for which existing treatments may not provide adequate cures or long-term control.

Assembly’s pipeline includes novel antiviral candidates designed to interfere with essential stages of viral replication.